Clinical trial

Efficiency Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone

NCT01516424

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2012-02-01

PhasePHASE3

Study timeline

Study start (unknown)2012-02-01Date precision: month

Registry last updated2018-11-27

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Schizophreniaunresolved

Interventions

BlonanserinDRUG

RisperidoneDRUG · verified · RxNorm: risperidone

Sponsors & collaborators

Marubeni Pharmaceuticals (Suzhou) Co., Ltd.lead sponsor

Mapped research locations

BeijingBeijing Municipality, China3 ChangshaHunan, China2 ShanghaiShanghai Municipality, China1 GuangzhouGuangdong, China1 NanjingJiangsu, China1 ChengduSichuan, China1 TianjinTianjin Municipality, China1 HarbinHeilongjiang, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01516424 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.